STI Knowledge and HPV Vaccine Acceptance in Bamako, Mali in 2012

NCT05767138 | Completed

• 1 other identifier: HPV Vaccine Survey
• Study Type: observational
• Target: 301
• Locations: 0 countries
• Sites: N/A

Brief Summary

Although screening for pre-cancerous cervical lesions and human papilloma virus (HPV) vaccination are accepted and effective means to prevent cervical cancer, women in Mali have limited access to these interventions. In addition, cervical cancer prevention by HPV vaccination has been controversial in some settings. To reduce cervical cancer prevalence and increase HPV vaccine uptake, it is important to understand the level of knowledge about cervical cancer screening and practices related to vaccination in at-risk populations. In this study, the level of knowledge about HPV and cervical cancer and attitudes towards vaccination were assessed among 301 participants (male and female, adults and adolescents) in a house-to-house survey in two urban neighborhoods in Bamako, Mali. The survey was combined with a brief educational session on HPV. Prior to the education session, overall knowledge of HPV infection and cervical cancer was very low: only 8% knew that HPV is a sexually transmitted infection (STI). Less than 20% of women had ever consulted a gynecologist and less than 3% had ever had cervical cancer screening. After hearing a description of HPV vaccine, more than 80% would accept HPV vaccination; fathers and husbands were identified as primary decisions makers and local clinics or the home as preferred sites for vaccination. This study provides information on STI knowledge and vaccine acceptance in Bamako, Mali in 2012, prior to the introduction of HPV vaccination.

Conditions

HPV; HPV-Related Cervical Carcinoma

Keywords

Mali; Bamako; Survey

Outcome Measures

Primary Outcomes (1)

• Participants' acceptance of the vaccine

  Number of participants willing to be vaccinated against HPV and their vaccination preferences after educational sessions

  immediately after the intervention

Secondary Outcomes (1)

• Knowledge of STIs, HPV, and Cervical Cancer

  immediately after the intervention

Study Arms (1)

Bamako Participants

301 male and female participants. Teenagers and adults. Living in two urban regions of Bamako.

Behavioral: HPV Vaccine Acceptance Survey

Interventions

HPV Vaccine Acceptance Survey BEHAVIORAL

Bamako Participants

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Participants were recruited between May and June 2011 in Mèkin-Sikoro and Djikoroni, two peri-urban communities of Bamako that have been site for previous population surveys. Adolescents were eligible if aged 12-17 years and living in the household, and if a guardian was available to provide consent. Adults (male and female) were eligible if aged \>18 years and living in the household. A total of 301 participants participated (150 living in households in Djikoroni, 151 living in Me´kin-Sikoro)

You may qualify if:

• years of age, with guardian consent
• years or older
• Male or Female
• Living in Mèkin-Sikoro and Djikoroni

You may not qualify if:

• years of age, without guardian consent
• \<12 years of age
• Living outside Mèkin-Sikoro and Djikoroni

Sponsors & Collaborators

• Global Alliance to Immunize Against AIDS Vaccine Foundation: lead
• Merck Sharp & Dohme LLC: collaborator

Study Officials

• Anne De Groot, MD

  GAIA Vaccine Foundation

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: ECOLOGIC OR COMMUNITY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 26, 2022
• First Posted: March 14, 2023
• Study Start: March 1, 2011
• Primary Completion: May 1, 2011
• Study Completion: June 1, 2011
• Last Updated: March 14, 2023

Record last verified: 2023-03

Data Sharing

• IPD Sharing: Will not share